Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 554-557

  Montineri, Arturo ^a   Nigro, Luciano ^a,b   Chiarenza, Annalisa ^b   Larocca, Licia ^a   La Rosa, Rosario ^a   Iacobello, Carmelo ^a   Di Raimondo, Francesco ^b   Fatuzzo, Filippo ^a  

^a Ferrarotto Hospital   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; PREDNISOLONE; RITUXIMAB; TELBIVUDINE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DNA; MONOCLONAL ANTIBODY; NUCLEOSIDE; PROTEIN BCL 2; PYRIMIDINONE DERIVATIVE; THYMIDINE; TUMOR MARKER;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; LIVER FUNCTION TEST; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; COMPLICATION; LYMPHOMA, B-CELL; MALE; METABOLISM; MIDDLE AGED; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CYCLOPHOSPHAMIDE; DNA; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NUCLEOSIDES; PREDNISOLONE; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINONES; THYMIDINE; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 77249126926     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903553961     Document Type: Letter

References (20)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Mele A, Tosti ME, Spada E, et al. Epidemiology of acute viral hepatitis: twenty years of surveillance through SEIEVA in Italy and a review of the literature. Rapporti ISTSAN 2006. pp 1-39.
3. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-1108.
4. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007;39:397-408.
5. Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005;74:158-165.
6. Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006;91:554-557.
7. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712.
8. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharingeal carcinoma with lamivudine. Am J Clin Oncol 2005;28:379-384.
9. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
10. Lok AS, Lai CL, Leung N, et al. Long term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
12. Cabrerizo M, Bartolome J, Caramelo C. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000;32:116-123.
13. Maini MK, Bertoletti A. How can the cellular immune response control hepatitis B virus replication? J Vir Hepat 2000;7:321-326.
14. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B reactivation during anticancer therapy. Hepatology 2006;43:209-220.
15. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13-23.
16. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006;4:666-676.
17. Coco B, Olivieri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14: 360-369.
18. Liaw YF, Gane E, Leung N, et al. 2-year globe trial results: telbivudine is superior to lamivudine in patients with chronichepatitis B. Gastroenterology 2009;136:486-495.
19. Keefee EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroeterol Hepatol 2007;5:890-897.
20. European Association for the study of the Liver. EASL Clinical Practice Guideline: Management of chronic hepatitis B. J Hepatol 2009;50:227-242.